Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Hepatology. 2009 May;49(5 Suppl):S166–S173. doi: 10.1002/hep.22899

Table 2. Predictive value for outcomes of early HBV DNA measurements during antiviral therapy.

Time Antiviral Predictive level Seroconversion Resistance Rate
Week 4 LMV HBV DNA <2000 IU/mL 100% PPV for HBeAg seroconversion -
Week 8 PEG/LMV HBV DNA > 104 copies/mL 92% NPV for HBeAg seroconversion -
Week 12 ADV >3 log10 decline in HBV DNA 87% HBeAg seroconversion (vs 24% if <3 log10) -
Week 24 TEL/LMV HBV DNA <300 copies/mL 41% HBeAg seroconversion (vs 4% if >104 copies/mL) 2% (vs 15% if HBV DNA >104 copies/mL)
Week 24 LMV HBV DNA <200 copies/mL - 8% (vs 64% if HBV DNA >104 copies/mL)

Abbreviations: SC, seroconversion; PPV, positive predictive value; NPV, negative predictive value, TEL, telbivudine, LMV, Lamivudine; PEG, pegylated interferon; ADV, adefovir; IU, international units;